Hostname: page-component-745bb68f8f-v2bm5 Total loading time: 0 Render date: 2025-02-11T17:25:40.088Z Has data issue: false hasContentIssue false
  • English
  • Français

Disclosing Conflicts of Interest in Clinical Research: Views of Institutional Review Boards, Conflict of Interest Committees, and Investigators

Published online by Cambridge University Press:  01 January 2021

Kevin P. Weinfurt ,
Joëlle Y. Friedman ,
Michaela A. Dinan ,
Jennifer S. Allsbrook ,
Mark A. Hall ,
Jatinder K. Dhillon  and
Jeremy Sugarman
Get access Rights & Permissions [Opens in a new window]

Extract

Investigator and institutional financial conflicts of interest have raised concerns about both the integrity of clinical research and protecting the rights and welfare of research participants. In response, professional groups and governmental bodies have issued guidance for managing conflicts of interest to minimize their potential untoward effects. Although a variety of approaches have been offered, a common protection is to disclose financial interests in research to potential research participants as part of the recruitment and informed consent process. This approach reinforces a basic norm of candor, ideally allowing potential research participants to evaluate whether financial interests should affect their decision to participate in research. Disclosure to potential research participants is viewed as an alternative to having regulators or research institutions limit or prohibit all financial interests in research, assuming that not all such interests are unacceptable.

Type
Independent
Information
Journal of Law, Medicine & Ethics , Volume 34 , Issue 3 , Fall 2006 , pp. 581 - 591
Copyright
Copyright © American Society of Law, Medicine and Ethics 2006

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Angell, M., “Is Academic Medicine for Sale?” New England Journal of Medicine 342 (2000): 1516–1518; Bodenheimer, T., “Uneasy Alliance – Clinical Investigators and the Pharmaceutical Industry,” New England Journal of Medicine 342 (2000): 1539–1544; Korenman, S. G., “Conflicts of Interest and Commercialization of Research,” Academic Medicine 68, no. 9 (suppl) (1993): S18–S22; Shalala, D., “Protecting Research Subjects – What Must Be Done,” New England Journal of Medicine 343 (2000): 808–810.CrossRefGoogle Scholar
Department of Health and Human Services, “Financial Relationships and Interests in Research Involving Human Subjects: Guidance for Human Subject Protection,” Federal Register 69 (2004): 26393–26397.Google Scholar
Weinfurt, K. P. Dinan, M. A. Allsbrook, J. S. et al., “Policies of Academic Medical Centers for Disclosing Conflicts of Interest to Potential Research Participants,” Academic Medicine 81 (2006): 113–118.CrossRefGoogle Scholar
45 C.F.R. § 46 (2005); 21 C.F.R. § 50 (2005); 21 C.F.R. § 56 (2005).CrossRefGoogle Scholar
Krueger, R. A., Focus Groups, 2nd edition (Thousand Oaks, CA: Sage Publications, 1994).Google Scholar
Faden, R. R. and Beauchamp, T. L., A History and Theory of Informed Consent (New York: Oxford University Press, 1986).Google Scholar
Id.Google Scholar
See Weinfurt, et al., supra note 3.Google Scholar
Cain, D. M. Loewenstein, G., and Moore, D. A., “The Dirt on Coming Clean: Perverse Effects of Disclosing Conflicts of Interest,” Journal of Legal Studies 34 (2005): 1–25.CrossRefGoogle Scholar
Boyd, E. A. Cho, M. K., and Bero, L. A., “Financial Conflict-of-Interest Policies in Clinical Research: Issues for Clinical Investigators,” Academic Medicine 78 (2003): 769–774.CrossRefGoogle Scholar
Id.; Resnik, D. B., “Disclosing Conflicts of Interest to Research Subjects: An Ethical and Legal Analysis,” Accountability in Research 11 (2004): 141–159; Schneider, C. E., “Reaching Disclosure,” Hastings Center Report 35 (2005): 12–13.CrossRefGoogle Scholar